Martin Rains, MD
Interventional Cardiology · Paducah, KYNPI 1063675551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,650 of the $44,559 with a category attached, or 62.1%. AstraZeneca accounts for 64.3% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2023 at $15,294 and has fallen 89.8% since, to $1,553 in 2025.
Across 572 payments — averaging $77.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$29K
- Medtronic$3K
- Edwards Lifesciences$3K
- Abbott$2K
- Novartis$1K
- Boston Scientific$779
- plus $6K from 33 others
What the payments were for
- Consulting fees$1,2453%
- Speaking & faculty fees$27,65062%
- Travel & lodging$2,8226%
- Food & beverage$12,82829%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $28,658 |
| Medtronic(2 entities) | 42 | $3,344 |
| Edwards Lifesciences | 48 | $3,157 |
| Abbott | 32 | $1,807 |
| Novartis | 71 | $1,240 |
| Boston Scientific | 26 | $779 |
| Abiomed | 10 | $658 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 47 | $607 |
| Pfizer | 43 | $597 |
| Inari Medical, Inc. | 9 | $567 |
| Johnson & Johnson | 36 | $552 |
| Amgen | 36 | $547 |
| E.r. Squibb & Sons, L.L.C. | 30 | $413 |
| Boehringer Ingelheim | 20 | $317 |
| Merck | 12 | $202 |
| Sanofi-aventis U.S. LLC | 10 | $182 |
| Lantheus Medical Imaging, Inc. | 10 | $181 |
| Philips North America LLC | 7 | $140 |
| Shockwave Medical, Inc | 4 | $98 |
| Irhythm Technologies, Inc. | 4 | $58 |
| Alnylam Pharmaceuticals Inc. | 3 | $49 |
| Portola Pharmaceuticals, LLC | 3 | $44 |
| Astellas Pharma US Inc | 2 | $37 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Stryker | 1 | $34 |
| Elutia, Inc. | 2 | $26 |
| ZOLL Circulation Inc | 1 | $25 |
| Braemar Manufacturing, LLC | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Chiesi USA, Inc. | 1 | $18 |
| Bayer | 1 | $18 |
| Cvrx, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Penumbra, Inc. | 1 | $16 |
| Atricure, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$27,976
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$1,593
- CoreValve Evolut$1,550
- MitraClip$1,013
- Micra$771
- FLOWTRIEVER CATHETER, S$436
- Impella$375
- PASCAL$249
- CT THROMBECTOMY SYSTEM KIT$200
- AVVIGO Guidance System$147
- Edwards SAPIEN 3 Transcatheter Heart Valve$137
- ENTRESTO$125
- WATCHMAN Access System$119
- AZURE XT DR MRI SURESCAN$113
- QUADRA ASSURA$112
- SAPIEN 3 Ultra RESILIA$108
- XARELTO$106
- Watchman$105
How this compares
$44,559 in reported general payments places this provider in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 310 | $263,930 |
| EntrestoSacubitril/Valsartan | 225 | $207,076 |
| FarxigaDapagliflozin Propanediol | 160 | $123,102 |
| JardianceEmpagliflozin | 121 | $100,291 |
| XareltoRivaroxaban | 80 | $94,385 |
| BrilintaTicagrelor | 107 | $63,863 |
| Repatha SureclickEvolocumab | 75 | $53,348 |
| MultaqDronedarone Hcl | 28 | $32,471 |
| Repatha SyringeEvolocumab | 13 | $13,419 |
| Praluent PenAlirocumab | 19 | $12,163 |
| Ranolazine ErRanolazine | 119 | $8,844 |
| Atorvastatin Calcium | 347 | $2,723 |
| Metoprolol Succinate | 232 | $2,315 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $2,286 |
| Prasugrel Hcl | 13 | $2,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $597 | $263,930310 claims |
| NovartisEntresto | $1,240 | $207,076225 claims |
| AstraZenecaFarxiga, Brilinta | $28,658 | $186,965267 claims |
| Boehringer IngelheimJardiance | $317 | $100,291121 claims |
| Johnson & JohnsonXarelto | $552 | $94,38580 claims |
| Sanofi-aventis U.S. LLCMultaq | $182 | $32,47128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Paducah
- James FordPaducah$67K
- Shankho GanguliPaducah$56K
- Timothy McDermottPaducah$17K
- Michael FaulknerPaducah$13K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.